{"id":"NCT00086515","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)","officialTitle":"A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-06-30","primaryCompletion":"2005-07-20","completion":"2007-02-02","firstPosted":"2004-07-05","resultsPosted":"2010-12-17","lastUpdate":"2017-05-05"},"enrollment":701,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type II"],"interventions":[{"type":"DRUG","name":"Sitagliptin (MK0431)","otherNames":["MK0431","sitagliptin phosphate","Januvia"]},{"type":"DRUG","name":"Placebo/Glipizide 5 mg","otherNames":[]},{"type":"DRUG","name":"Metformin","otherNames":[]},{"type":"DRUG","name":"Pioglitazone","otherNames":["ACTOS"]}],"arms":[{"label":"Sitagliptin 100 mg","type":"EXPERIMENTAL"},{"label":"Placebo / Glipizide 5 mg","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.","primaryOutcome":{"measure":"Change From Baseline in Hemoglobin A1C (A1C) at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Sitagliptin 100 mg","deltaMin":-0.67,"sd":null},{"arm":"Placebo / Glipizide 5 mg","deltaMin":-0.02,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["17130197","18476982"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":54,"n":464},"commonTop":["Upper Respiratory Tract Infection","Hypoglycaemia","Influenza","Nasopharyngitis","Back Pain"]}}